Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?

New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Publication date: Available online 18 June 2019Source: Gynecologic Oncology ReportsAuthor(s): David W. Doo, Lyse A. Norian, Rebecca C. ArendAbstractOvarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with an improved response to chemotherapy and better overall prognosis. Given the success of checkpoint inhibitors in the treatment of other malignancies, there has been an attempt to replicate these results in ovarian cancer clinical...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Advanced ovarian cancer is frequently treated with combination chemotherapy, but high recurrence rates show the need for therapies that can produce durable responses and extend overall survival. Bispecific antibodies that interact with tumor antigens on cancer cells and activating receptors on immune cells offer an innovative immunotherapy approach. Here, we describe a human bispecific antibody (REGN4018) that binds both Mucin 16 (MUC16), a glycoprotein that is highly expressed on ovarian cancer cells, and CD3, thus bridging MUC16-expressing cells with CD3+ T cells. REGN4018 induced T cell activation and killing of MUC16-e...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
Conclusion.Our study revealed substantial treatment gaps with respect to surgery and adequate chemotherapy. Higher stage, residual tumor and lack of chemotherapy impaired the outcome. Access to higher standards of ovarian cancer treatment is urgently needed in Ethiopia.Implications for Practice.Ovarian cancer is often a fatal disease in high resource settings; now it is also becoming important in Ethiopia. This study included 485 women with malignant ovarian tumors treated in Addis Ababa who had a mean age of only 46 years because of the young population structure. Three quarters had the typical epithelial cancer, with hal...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Gynecologic Oncology, Global Health and Cancer Source Type: research
Conclusion.Baseline heart rate and the frequency of hypomagnesemia episodes during treatment are prognostic of survival for patients with advanced ovarian cancer receiving carboplatin‐containing chemotherapy and tumor reductive surgery. Future research is needed for strategies to detect and prevent hypomagnesemia in this patient population.Implications for Practice.Despite standard laboratory tests and intravenous magnesium replacement prior to each cycle of chemotherapy, hypomagnesemia remains a common side effect of platinum‐based chemotherapy. This study revealed that frequent occurrence of hypomagnesemia during the...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Gynecologic Oncology, Head and Neck Cancers Source Type: research
rt Berx Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage, and the frequent development of resistance to current chemotherapeutic regimens. Growing evidence demonstrates that apart from its role in ovarian cancer progression, epithelial-to-mesenchymal transition (EMT) can promote chemotherapy resistance. In this review, we will highlight the contribution of EMT to the distinct steps of ovarian cancer progression. In add...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionAnatomical varieties of the ureter are of utmost importance for the surgeons, because they increase the possibility of iatrogenic ureteral injury. Ureteral injuries are severe complications of pelvic operations and may increase morbidity and even cause mortality.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Most women with advanced epithelial ovarian cancer develop recurrent disease despite maximal surgical cytoreduction and adjuvant platinum-based chemotherapy. In observational studies secondary cytoreductive surgery has been associated with improved survival, however its use is controversial, because there are concerns that the improved outcomes may reflect selection bias rather than the superiority of secondary surgery.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Original Research: Gynecology Source Type: research
Conclusion: A multifunctional nanoplatform based on phase-transitional Pt(IV) NP-cRGD with US exhibited excellent echogenic signals, brilliant therapeutic efficacy and limited side effect, suggesting precise theranostics against ovarian cancer.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: The inability to completely excise peritoneal metastatic tumors by debulking surgery as well as resistance to chemotherapy are the major clinical challenges for ovarian cancer treatment. This targeted cancer therapy has the potential for the development of effective treatment for metastatic ovarian cancer.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: These findings characterize a novel role of ERα in mediating the molecular connection between hormone and HRR in EOC and encourage hormone replacement therapy for EOC patients.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Ovarian Cancer | Ovaries